Kezar Life Sciences, Inc. (KZR)

Market Cap	601.65M
Revenue (ttm)	n/a
Net Income (ttm)	-60.89M
Shares Out	68.37M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	422,276
Open	8.51
Previous Close	8.61
Day's Range	8.47 - 8.91
52-Week Range	4.31 - 18.55
Beta	0.15
Analysts	Buy
Price Target	19.13 (+117.4%)
Earnings Date	Nov 7, 2022

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products includ...

• Industry: Biotechnology
• IPO Date: Jun 21, 2018
• CEO: John Fowler
• Employees: 56
• Stock Exchange: NASDAQ
• Ticker Symbol: KZR

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for KZR stock is "Buy." The 12-month stock price forecast is 19.13, which is an increase of 117.39% from the latest price.

Price Target

$19.13

(117.39% upside)

Analyst Consensus: Buy

Stock Forecasts